Osteoarthritis
Exercise, drug sequence data top headlines for Osteoporosis Awareness Month
In honor of Osteoporosis Awareness Month in May, advocacy organizations used social media to spread the word about the disease, including tips for patients on how to better manage their disease.
EULAR: Routine, proactive therapeutic drug monitoring unnecessary in RMDs
Routine, proactive therapeutic drug monitoring for patients receiving biopharmaceuticals for rheumatic and musculoskeletal diseases is not recommended, according to new points-to-consider published by EULAR.
Impacts of ‘understudied’ calcium pyrophosphate deposition remain unknown
Among the many unanswered questions about calcium pyrophosphate deposition — formerly called “pseudogout” — perhaps the most important is whether it causes osteoarthritis, a speaker said at the Congress of Clinical Rheumatology East.
Patients receiving tramadol for osteoarthritis more likely to die, fracture hip
Patients who receive tramadol for osteoarthritis demonstrate an increased risk for hip fractures, venous thromboembolism and mortality, compared with those treated with NSAIDs, according to data published in Arthritis Research and Therapy.
Subcutaneous tanezumab, NSAIDs improve osteoarthritis pain
Tanezumab and NSAIDs both demonstrated early and sustained improvement in pain and function among patients with knee or hip osteoarthritis, according to data published in Arthritis Research and Therapy.
Patients with OA, dementia have fewer ‘hospital-free years’ than those without dementia
Patients with osteoarthritis who developed dementia were more likely than their counterparts without dementia to be hospitalized for ambulatory care services, according to a speaker at the 2022 OARSI World Congress.
COVID-19 has caused ‘significant negative impacts’ on patients with musculoskeletal pain
The COVID-19 pandemic has wrecked “significant negative impacts” on pain, function and treatment accessibility for individuals with chronic musculoskeletal pain, according to a speaker at the 2022 OARSI World Congress.
High tibial osteotomy may ‘reduce risk’ for total knee replacement
High tibial osteotomy leading to large changes in knee dynamics may reduce the likelihood of total knee replacement in patients with knee osteoarthritis, according to a speaker at the 2022 OARSI World Congress.
Cumulative loading, degradation biomarker weakly associated with knee cartilage thickness
Mechanical load plus a biomarker that reflects cartilage degradation may predict worsening cartilage thickness in knee osteoarthritis, according to a speaker at the 2021 OARSI World Congress.
‘Disappointing’ data reveal modest benefit of exercise over pain meds in knee OA
A meta-analysis comparing exercise, opioids and NSAIDs yielded “disappointing” and inconsistent results, in which exercise generally demonstrated some benefit over opioids and NSAIDs, according to a speaker at the 2022 OARSI World Congress.